Over the past 5 months, since the first reported case of COVID-19, Glenmark mobilized its teams and development process started at its Research and Development (R&D) facility in Navi Mumbai. The entire process from R&D, to producing the Active Pharmaceutical Ingredient (API) at Ankleshwar (Gujarat) and manufacturing the formulations at Baddi (Himachal Pradesh) have been done in-house and is a significant achievement as part of “Make in India”. Despite investing significantly throughout the process of manufacturing FabiFlu, Glenmark has managed to keep the pricing of FabiFlu economical as compared to its price in other countries. FabiFlu in India costs Rs 103/tab, while, its price as INR is higher in the remaining countries. The total cost of treatment for mild to moderate COVID-19 cases using FabiFlu will be around Rs 7,000.
Glenmark’s Fabiflu for mild to moderate COVID-19 cases
